CC - Compound Libraries - Triad Therapeutics

Friday, August 26, 2005 Print

Triad Therapeutics have developed a proprietary technology named Integrated Object-Oriented PharmacoEngineering (IOPE®) to leverage genomic information and dramatically shorten the path from target to lead compound.

Using Triad’s unique NMR methods to guide construction, we are able to build object-oriented libraries to quickly identify high-affinity, nanomolar inhibitors. The reuseable libraries are specific to important families of enzymes that have yielded drugs worth more than $20 billion in the current pharmaceutical market. Our proprietary methodology enables us to mine these drug-rich gene families quickly, efficiently and with what we believe is an increased probability of moving from target to therapeutic drug.